Overview
ONCY market data
Price History
ONCY price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for ONCY. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
8-K filing — ONCOLYTICS BIOTECH INC (ONCY)SEC EDGAR · Jul 20, 2026, 1:03 PM
Oncolytics Biotech Receives FDA's Fast Track Designation To Pelareorep In Combination With A Checkpoint Inhibitor Treat Squamous Cell Carcinoma Of Anal CanalBenzinga · Jul 20, 2026, 1:01 PM
Oncolytics Biotech shares are trading higher after the company announced that it received FDA Fast Track Designation for pelareorep evaluation in certain forms of colorectal cancer.Benzinga · Jul 13, 2026, 3:03 PM
Oncolytics Biotech Receives FDA Fast Track Designation For Pelareorep Evaluation In Certain Forms Of Colorectal CancerBenzinga · Jul 13, 2026, 1:03 PM
Oncolytics Biotech Receives New U.S. Patent For Its Proprietary Manufacturing Process For PelareorepBenzinga · Jun 16, 2026, 1:10 PM
Oncolytics Biotech Promotes John McAdory To COOBenzinga · Jun 2, 2026, 1:05 PM
Oncolytics Biotech Announces Initial Data From Preclinical Study Supporting Further Evaluation Of Pelareorep In Combination With RAS Inhibitor Modalities In Solid Tumor ModelBenzinga · Jun 1, 2026, 1:08 PM
HC Wainwright & Co. Reiterates Buy on Oncolytics Biotech, Maintains $10 Price TargetBenzinga · May 26, 2026, 10:16 AM
Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal TumorsGlobenewswire Inc · May 22, 2026, 1:15 PM
"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming TherapiesGlobenewswire Inc · May 14, 2026, 3:15 PM